APS-2-79

Research use only, not for human use.

A small molecule compound that modulates KSR-dependent MAPK signalling by antagonizing RAF heterodimerization.

A small molecule compound that modulates KSR-dependent MAPK signalling by antagonizing RAF heterodimerization, and the conformational changes required for phosphorylation and activation of KSR-bound MEK (KSR2 IC50=120 nM); binds to the KSR2-MEK1 complex and impedes the assembly of RAF–KSR–MEK complexes, suppresses KSR-stimulated MEK and ERK phosphorylation and suppresses oncogenic Ras mutations; enhances the efficacy of Trametinib against cancer cell lines containing K-Ras mutations.

APS-2-79 (5 μM) suppresses KSR-stimulated MEK and ERK phosphorylation in 293H cells.APS-2-79 (1 μM) enhances the efficacy of the clinical MEK inhibitor trametinib within cancer cell lines containing K-Ras mutations.

——

APS 2-79 | APS2-79

MAPK/ERK Signaling

MEK

MEK

Cancer

——

2002381-25-9

387.4312

C23H21N3O3

>98% (HPLC)

DMSO: ≥ 33 mg/mL

CC1=CC(OC2=CC=CC=C2)=CC=C1NC3=C4C=C(OC)C(OC)=CC4=NC=N3

4-Quinazolinamine, 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)-

(-20℃)

With Ice Pack

≥ 2 years